Market Place
Sourcing Support
Bylvay® Data Shows Improvement In Severe Itch & Serum Bile Acids
18 Nov 2024 //
GLOBENEWSWIRE
Ipsen picks up EU approvals for rare disease meds Kayfanda
24 Sep 2024 //
GLOBENEWSWIRE
Ipsen Pharma`s Kayfanda (odevixibat) Receives Approval in Europe
19 Sep 2024 //
EMA
Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay
13 Nov 2023 //
PR NEWSWIRE
Ipsen updates on E.U. MaAA for odevixibat in Alagille syndrome
23 Oct 2023 //
GLOBENEWSWIRE
Albireo`s Bylvay (Odevixibat) Approved In Europe
05 Jul 2023 //
EMA
EQT Private Equity to sell Ellab, following transformation into a validation
21 Jun 2023 //
PR NEWSWIRE
Jadeite Medicines Receives Orphan Drug Designation for Odevixibat in (PFIC)
20 Jun 2023 //
PR NEWSWIRE
After Albireo buyout, Ipsen`s Bylvay picks up new use
14 Jun 2023 //
FIERCE PHARMA
Ipsen to present new Bylvay (odevixibat) data at annual ESPGHAN congress
17 May 2023 //
GLOBENEWSWIRE
Albireo Submits Bylvay® Alagille Syndrome Regulatory Filings to FDA and EMA
19 Dec 2022 //
GLOBENEWSWIRE
Reimbursed Access to Bylvay Approved in France for Patients with PFIC 1 & 2
30 Nov 2022 //
GLOBENEWSWIRE
Bylvay® (odevixibat) Data Presented at AASLD The Liver Meeting® 2022
07 Nov 2022 //
GLOBENEWSWIRE
Albireo to Present Late Breaking Bylvay® (odevixibat) Data at AASLD 2022
01 Nov 2022 //
GLOBENEWSWIRE
Albireo Presents Data on Greater Efficacy in PFIC with Earlier Bylvay® NASPGHAN
13 Oct 2022 //
GLOBENEWSWIRE
Albireo Reports Positive Topline Data from Phase 3 Trial of Bylvay
12 Oct 2022 //
GLOBENEWSWIRE
Albireo`s Bylvay aces test in Alagille syndrome, setting for liver disease nod
11 Oct 2022 //
FIERCEPHARMA
Italian Medicines Agency Approves Reimbursed Access to Bylvay® (odevixibat)
06 Sep 2022 //
GLOBENEWSWIRE
Medison Pharma Expands Partnership with Albireo to a Multi-Regional Agreement
16 Aug 2022 //
PRNEWSWIRE
Albireo Reports Q2 2022 Financial Results and Business Update
15 Aug 2022 //
GLOBENEWSWIRE
Albireo Presents New Bylvay (odevixibat) Data at Annual ESPGHAN Congress
24 Jun 2022 //
GLOBENEWSWIRE
Albireo Completes Enrollment in Pivotal Phase 3 ASSERT Study of BylvayTM
29 Mar 2022 //
GLOBENEWSWIRE
NICE recommends Albireo’s Bylvay (odevixibat) for all PFIC types
23 Feb 2022 //
PHARMAFILE
Albireo CMO Horn exits 5 months after US, EU approvals
10 Dec 2021 //
FIERCEBIOTECH
Albireo Announces Bylvay® (odevixibat) Now Available in Germany
15 Sep 2021 //
GLOBENEWSWIRE
Albireo Receives UK MHRA Approval of Bylvay® (odevixibat)
08 Sep 2021 //
BIOSPACE
Albireo`s Bylvay (odevixibat) Receives Approval in Europe
28 Jul 2021 //
EMA
Albireo Announces Expanded Ph 3 Data on Bylvay & A3907
21 Jun 2021 //
GLOBENEWSWIRE
Albireo Presents Odevixibat Commercialization Road to $1 Billion
11 Feb 2021 //
GLOBENEWSWIRE
Albireo Initiates Global Phase 3 Trial of Odevixibat in Alagille Syndrome
17 Dec 2020 //
ALBIREOPHARMA
Albireo Initiates Global Phase 3 Clinical Trial of Odevixibat
17 Dec 2020 //
PRESS RELEASE
Albireo submits rare liver disease med odevixibat to FDA and EMA
11 Dec 2020 //
PHARMATIMES
Odevixibat Reduces Pruritus, Serum Bile Acid in Children With Progressive
16 Nov 2020 //
FIRSTWORDPHARMA
New Phase 3 Data at AASLD Show Durable Response to Odevixibat
13 Nov 2020 //
GLOBENEWSWIRE
Albireo’s Odevixibat PFIC Phase 3 Results Accepted for AASLD Late-Breakers
02 Nov 2020 //
GLOBENEWSWIRE
